B.Riley Downgrades Madrigal Pharmaceuticals (MDGL) to Sell
Tweet
Share
E-mailGet Alerts MDGL Hot Sheet
Price: $536.20 --0%
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 9 | New: 6
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 9 | New: 6
Join SI Premium – FREE
B.Riley analyst Mayank Mamtani downgraded Madrigal Pharmaceuticals (NASDAQ: MDGL) from Neutral to Sell with a price target of $155.00.
For an analyst ratings summary and ratings history on Madrigal Pharmaceuticals click here. For more ratings news on Madrigal Pharmaceuticals click here.
Shares of Madrigal Pharmaceuticals closed at $236.54 yesterday.
You May Also Be Interested In
- Cantor Fitzgerald Downgrades Better Home & Finance Holding (BETR) to Neutral
- BofA Securities Downgrades StubHub Holdings (STUB) to Underperform
- BNP Paribas Exane Downgrades Alcon Inc. (ALC:SW) (ALC) to Neutral
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
